An analysis of regulatory documents and what they may mean for clinicians and patient care
Recent Freedom of Information documents released to Women Speak Tasmania provide insight into how the Australian Health Practitioner Regulation Agency (AHPRA) is developing its National Scheme LGBTIQA+ Equity and Inclusion Strategy. The documents show AHPRA has committed to using external inclusion frameworks, including the Rainbow Tick standards and ACON’s workplace programs, as part of its long-term regulatory and organisational planning.
The documents raise broader questions about how concepts such as “cultural safety” are being interpreted within healthcare regulation, and whether clinicians may increasingly feel pressure to adopt affirmation-led approaches in areas where evidence and international practice remain under active debate.
What the AHPRA documents show
In February 2024, AHPRA’s National Executive approved the development of a dedicated LGBTIQA+ strategy. According to the internal papers obtained under FOI:
“Ahpra has committed to two external quality frameworks — Rainbow Tick and The Australian Workplace Equality Index (AWEI) — to guide its development of a National Scheme LGBTIQA+ equity and inclusion strategy…”
The same documents indicate the strategy is intended to influence future regulatory processes and workplace policies over a three-to-five-year period and will feed into the broader 2025 National Scheme strategy.
At face value, this may appear administrative. However, the frameworks being adopted carry specific assumptions about healthcare practice and service delivery — particularly in relation to gender identity.
Rainbow Tick and “cultural safety”
AHPRA’s strategy references the six Rainbow Tick standards developed by Rainbow Health Australia. Of particular relevance is Standard 6:
“Services and programs identify, assess, analyse and manage risks to ensure the cultural safety of LGBTIQ service users.”
Within Rainbow Tick and related guidance materials, “cultural safety” is generally framed around affirming a person’s self-identified gender and reducing experiences perceived as invalidating or discriminatory.
Critics argue that when such frameworks are embedded into regulatory systems, clinicians may begin to interpret exploratory or cautious approaches as professionally risky — even where those approaches are clinically justified.
Supporters, on the other hand, argue these frameworks are intended to reduce stigma and improve healthcare access for vulnerable populations.
The key issue is whether a regulatory body can incorporate advocacy-based inclusion frameworks while still preserving open clinical inquiry and independent professional judgement.
Professional codes already require respectful care
Australia’s existing professional codes already require practitioners to treat patients respectfully and without discrimination.
The Psychology Board of Australia’s Code of Conduct emphasises culturally safe and reflective practice. Nursing and medical codes similarly require practitioners to provide equitable care and respect diversity.
Importantly, however, these codes do not explicitly require immediate affirmation of a patient’s stated gender identity, nor do they prohibit exploratory therapy or broader psychological assessment.
This distinction matters because exploratory approaches may involve assessing underlying factors contributing to distress, including trauma, autism spectrum conditions, anxiety, depression, family dynamics, or social influences. Many clinicians consider such assessment a routine part of evidence-based mental healthcare.
The concern raised by some practitioners is that the regulatory environment may increasingly blur the line between respectful care and compulsory affirmation.
Regulatory pressure and professional risk
For clinicians working in this area, the issue is not necessarily what formal codes say, but how regulatory expectations are perceived and enforced in practice.
The recent case involving Queensland psychiatrist Dr Andrew Amos drew national attention after restrictions were imposed following complaints relating to his public comments on youth gender medicine, despite the absence of patient complaints.
The matter has become part of a wider debate about whether doctors who publicly advocate caution, or who prioritise psychological exploration before medical intervention, may face increased professional scrutiny.
Some clinicians argue this creates a chilling effect within medicine, discouraging open discussion about evidence quality, long-term outcomes, and alternative treatment pathways.
International developments are shifting the debate
The debate is occurring against a backdrop of significant international change.
The 2024 Cass Review in the United Kingdom concluded that the evidence base for puberty blockers and cross-sex hormones in minors was “remarkably weak” and recommended a more holistic model of care centred on comprehensive psychological assessment.
Following the review, NHS England restricted the routine use of puberty blockers outside formal research settings.
Other European countries, including Sweden and Finland, have also moved toward more cautious approaches for minors, citing uncertainty around long-term outcomes and evidence quality.
These developments have intensified scrutiny of affirmation-led models internationally and prompted calls for stronger evidence standards and independent oversight.
A broader question about regulation
The documents obtained through FOI do not show AHPRA explicitly instructing doctors to affirm patients or abandon clinical judgement. However, they do indicate that specific ideological and advocacy-based frameworks are becoming increasingly embedded within the culture and strategy of Australia’s health regulator.
That raises an important question for public discussion:
Should healthcare regulators align themselves with particular cultural or advocacy frameworks, or should they remain more clearly focused on evidence-based standards, open scientific debate, and the protection of independent clinical judgement?
As national reviews of youth gender medicine continue in Australia and overseas, this question is likely to become increasingly significant — not only for clinicians, but for patients and families seeking confidence that medical decisions are guided by the best available evidence and robust clinical oversight.